Abstract
Although health practitioners traditionally have not been trained in the medical management of obesity, they attain expertise in the treatment of its comorbidities—those conditions associated with, exacerbated by, or even caused by obesity, such as coronary artery disease, hypertension, type 2 diabetes, obstructive sleep apnea, degenerative joint disease, cancers (endometrium, colon, renal cell, breast, and prostate), gout, nonalcoholic steatohepatitis (NASH), polycystic ovary (PCO) syndrome, and other gynecologic conditions (Table 2-1).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999–2002. JAMA 2004;291:2847–2850.
Mokdad A, Marks J, Stroup D, Gerberding J. Actual causes of death in the Unites States, 2000. JAMA 2004;291:1238–1245.
Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB. Years of life lost due to obesity. JAMA 2003;289:187–193.
Dietz WH. Overweight in childhood and adolescence. N Engl J Med 2004;350:855–857.
Overweight, obesity, and health risk. National Task Force on the Prevention and Treatment of Obesity. Arch Intern Med 2000;160:898–904.
Lenfant C. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Bethesda: National Institutes of Health, 1998.
Savel RH, Gropper MA, Macura JM, Lazzaro RS. Management of the Critically Ill Obese Patient. www.uptodate. com, 2004.
Brolin RE. Gastric bypass. Surg Clin North Am 2001;81:1077–1095.
Yanovski SZ, Yanovski JA. Obesity. N Engl J Med 2002;346: 591–602.
Methods for voluntary weight loss and control. NIH Technology Assessment Conference Panel. Consensus Development Conference, 30 March to 1 April 1992. Ann Intern Med 1993;119:764–770.
Roldan EO. Childhood and Adolescent Obesity—Treatment of the Obese Patient. American Board of Bariatric Medicine Review Course, Scottsdale, Arizona, May 5, 2004.
Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433–438.
Blackburn G. Effect of degree of weight loss on health benefits. Obes Res 1995;3(suppl 2):211s–216s.
National Task Force on the Prevention and Treatment of Obesity NIH. Very low-calorie diets. JAMA 1993;270:967–974.
National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994;89:1333–1445.
Munoz KA, Krebs-Smith SM, Ballard-Barbash R, Cleveland LE. Food intakes of US children and adolescents compared with recommendations. Pediatrics 1997;100:323–329.
Food and Nutrition Intakes by Children 1994–1996, 1998. U.S. Department of Agriculture, Agricultural Research Service, 1999:Table Set 17.
Epstein LH, Gordy CC, Raynor HA, Beddome M, Kilanowski CK, Paluch R. Increasing fruit and vegetable intake and decreasing fat and sugar intake in families at risk for childhood obesity. Obes Res 2001;9:171–178.
Daniels SR. Abnormal weight gain and weight management: are carbohydrates the enemy? J Pediatr 2003;142: 225–227.
Brehm BJ, Seeley RJ, Daniels SR, D’Alessio DA. A randomized trial comparing a very low carbohydrate diet and a calorie-restricted low fat diet on body weight and cardio-vascular risk factors in healthy women. J Clin Endocrinol Metab 2003;88:1617–1623.
Samaha FF, Iqbal N, Seshadri P, et al. A low-carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med 2003;348:2074–2081.
Foster GD, Wyatt HR, Hill JO, et al. A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med 2003; 348:2082–2090.
Slentz CA, Duscha BD, Johnson JL, et al. Effects of the amount of exercise on body weight, body composition, and measures of central obesity: STRRIDE—a randomized controlled study. Arch Intern Med 2004;164:31–39.
Ross R, Dagnone D, Jones PJ, et al. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial. Ann Intern Med 2000;133:92–103.
Jakicic JM, Marcus BH, Gallagher KI, Napolitano M, Lang W. Effect of exercise duration and intensity on weight loss in overweight, sedentary women: a randomized trial. JAMA 2003;290:1323–1330.
Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol 2002;40:1531–1540.
Wadden TA, Foster GD. Behavioral treatment of obesity. Med Clin North Am 2000;84:441–461, vii.
Methods for Voluntary Weight Loss and Control. Proceedings of NIH Technology Assessment Conference. Bethesda, Maryland, 30 March-1 April 1992. Ann Intern Med 1993; 119:641–770.
Fletcher AM. Thin for Life. Boston, Houghton Mifflin, 1994.
Klem ML, Wing RR, McGuire MT, Seagle HM, Hill JO. A descriptive study of individuals successful at long-term maintenance of substantial weight loss. Am J Clin Nutr 1997;66:239–246.
Shick SM, Wing RR, Klem ML, McGuire MT, Hill JO, Seagle H. Persons successful at long-term weight loss and maintenance continue to consume a low calorie, low fat diet. J Am Dietetic Assoc 1998;98:408–413.
McGuire MT, Wing RR, Klem ML, Seagle HM, Hill JO. Long-term maintenance of weight loss: do people who lose weight through various weight loss methods use different behaviors to maintain their weight? Int J Obes 1998;22:572–577.
Hendricks EJ. Pharmacotherapy—Treatment of the Obese Patient, 2004 American Board of Bariatric Medicine Review Course, Scottsdale, Arizona, 2004.
Obesity National Task Force on the Prevention and Treatment of Obesity. Long-term pharmacotherapy in the management of obesity. JAMA 1996;276:1907–1915.
Munro JF, MacCuish AC, Wilson EM, Duncan LJ. Comparison of continuous and intermittent anorectic therapy in obesity. Br Med J 1968;1:352.
Stallone DD. Long-term use of appetite suppressant medications: rationale and recommendations. Drug Dev Res 1992;26:1–20.
Stafford RS, Radley DC. National trends in antiobesity medication use. Arch Intern Med 2003;163:1046–1050.
Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE. A population-based study of appetitesuppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med 1998;339:719–724.
Khan MA, Herzog CA, St Peter JV, et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med 1998;339:713–718.
Weissman NJ, Tighe JF Jr, Gottdiener JS, Gwynne JT. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. N Engl J Med 1998;339:725–732.
Kernan WN, Viscolli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000;343:1826.
Bray GA, Blackburn GL, Ferguson JM, et al. Sibutramine produces dose-related weight loss. Obes Res 1999;7:189–198.
Fujioka K, Seaton TB, Rowe E, et al. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2000;2:175–187.
Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord 1997;21(suppl 3):S12–23.
Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy 2000;20:270–279.
Tonstad S, Pometta D, Erkelens DW, et al. The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol 1994;46:405–410.
Hukshorn CJ, Saris WH, Westerterp-Plantenga MS, Farid AR, Smith FJ, Campfield LA. Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men. J Clin Endocrinol Metab 2000;85: 4003–4009.
Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like pep tide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998;101:515–520.
Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003;349:941–948.
Ettinger MP, Littlejohn TW, Schwartz SL, et al. Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study. JAMA 2003;289:1826–1832.
Cota D, Marsicano G, Tschop M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003; 112:423–431.
Bent S, Tiedt TN, Odden MC, Shlipak MG. The relative safety of ephedra compared with other herbal products. Ann Intern Med 2003;138:468–471.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
March, V., Pierce, K. (2007). The Medical Management of Obesity. In: Schauer, P.R., Schirmer, B.D., Brethauer, S.A. (eds) Minimally Invasive Bariatric Surgery. Springer, New York, NY. https://doi.org/10.1007/978-0-387-68062-0_2
Download citation
DOI: https://doi.org/10.1007/978-0-387-68062-0_2
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-68058-3
Online ISBN: 978-0-387-68062-0
eBook Packages: MedicineMedicine (R0)